What’s new in lipid management for people with recurrent myocardial infarction (MI)?

Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Shaun Goodman, a Cardiologist and Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael’s Hospital, and a Professor and Heart & Stroke Foundation of Ontario (Polo) Chair at the University of Toronto’s Department of Medicine. He is Co-Director of the Canadian VIGOUR (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research) Centre.

This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients with recurrent MI. Our experts also dive into the topics of why this patient subgroup is at particularly high risk for subsequent major adverse cardiovascular events and may benefit from more aggressive treatment intensification beyond maximally tolerated statins. They touch on the use of lipid-lowering therapies ezetimibe and PCSK9 inhibitors in those with recurrent MI and discuss the clinical evidence from the landmark ODYSSEY OUTCOMES and FOURIER trials.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr.  Thanassoulis:

• Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence.

Dr. Goodman:

• Direct financial relationship including receipt of honoraria: Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health). Membership on advisory boards or speaker’s bureau: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma. Funded grants, research or clinical trials: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi.